Compare HOYA Corp. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 20.17%
- Company has very low debt and has enough cash to service the debt requirements
2
With a growth in Net Sales of 1.39%, the company declared Very Positive results in Mar 26
3
With ROE of 24.50%, it has a fair valuation with a 9.27 Price to Book Value
4
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 8,913,833 Million (Large Cap)
38.00
NA
0.00%
-0.54
25.00%
8.74
Revenue and Profits:
Net Sales:
248,130 Million
(Quarterly Results - Mar 2026)
Net Profit:
53,912 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.86%
0%
-2.86%
6 Months
10.63%
0%
10.63%
1 Year
55.7%
0%
55.7%
2 Years
42.62%
0%
42.62%
3 Years
57.6%
0%
57.6%
4 Years
125.5%
0%
125.5%
5 Years
78.35%
0%
78.35%
HOYA Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.50%
EBIT Growth (5y)
13.76%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.53
Sales to Capital Employed (avg)
0.83
Tax Ratio
22.43%
Dividend Payout Ratio
34.95%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
48.78%
ROE (avg)
20.17%
Valuation key factors
Factor
Value
P/E Ratio
38
Industry P/E
Price to Book Value
9.27
EV to EBIT
33.13
EV to EBITDA
27.59
EV to Capital Employed
18.41
EV to Sales
9.81
PEG Ratio
1.84
Dividend Yield
NA
ROCE (Latest)
55.57%
ROE (Latest)
24.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 4 Foreign Institutions (0.06%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
248,130.00
244,720.00
1.39%
Operating Profit (PBDIT) excl Other Income
90,103.00
88,025.00
2.36%
Interest
506.00
497.00
1.81%
Exceptional Items
-2,322.00
-514.00
-351.75%
Consolidate Net Profit
53,912.00
91,176.00
-40.87%
Operating Profit Margin (Excl OI)
296.80%
297.90%
-0.11%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 1.39% vs 4.36% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -40.87% vs 65.89% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
947,749.00
866,032.00
9.44%
Operating Profit (PBDIT) excl Other Income
439,381.00
392,211.00
12.03%
Interest
1,764.00
1,326.00
33.03%
Exceptional Items
20,332.00
-4,733.00
529.58%
Consolidate Net Profit
251,451.00
201,750.00
24.63%
Operating Profit Margin (Excl OI)
402.20%
396.80%
0.54%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 9.44% vs 13.56% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 24.63% vs 10.51% in Mar 2025
About HOYA Corp. 
HOYA Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






